<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="166416">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01810198</url>
  </required_header>
  <id_info>
    <org_study_id>CONSERVE</org_study_id>
    <nct_id>NCT01810198</nct_id>
  </id_info>
  <brief_title>Coronary Computed Tomographic Angiography for Selective Cardiac Catheterization</brief_title>
  <acronym>CONSERVE</acronym>
  <official_title>Coronary Computed Tomographic Angiography for Selective Cardiac Catheterization: Relation to CardioVascular Outcomes, Cost Effectiveness and Quality of Life</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MDDX LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GE Healthcare</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>MDDX LLC</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the effectiveness, safety, and cost efficiency associated with a CCTA-guided
      selective catheterization strategy for stable patients but without known CAD and an American
      Heart Association/ American College of Cardiology Class II indication for non-emergent
      invasive coronary angiography.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A prospective, randomized controlled multicenter trial to determine the clinical and cost
      effectiveness of a &quot;selective catheterization&quot; strategy versus a &quot;direct catheterization&quot;
      strategy for stable patients with suspected but without known CAD and clinical indication
      for non-emergent invasive coronary angiography.  Subjects in the &quot;selective catheterization&quot;
      arm will be followed for a primary endpoint of non-inferiority for rates of major adverse
      cardiac events (MACE) as compare to subjects in the &quot;direct catheterization&quot; strategy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Anticipated">May 2018</completion_date>
  <primary_completion_date type="Anticipated">February 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic</study_design>
  <primary_outcome>
    <measure>MACE Endpoints</measure>
    <time_frame>4 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Death
Non-fatal myocardial infarction
Unstable angina (including new onset angina or those requiring hospitalization, revascularization or that are troponin-positive)
Stroke
Urgent or emergent coronary revascularization
Cardiovascular hospitalization (including for angina, heart failure or other)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Additional MACE Endpoints</measure>
    <time_frame>4 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>The primary composite MACE endpoint plus major bleeding.
The primary composite MACE endpoint plus major bleeding or need for urgent/ emergent surgery due to hemorrhage.
The primary composite MACE endpoint plus major bleeding plus need for urgent/ emergent surgery due to hemorrhage plus need for major transfusion.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Economic</measure>
    <time_frame>4 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>The secondary economic endpoint is within-trial cardiovascular costs*.
*Costs will include index- and downstream CAD-related costs related to diagnostic testing, medications, hospitalizations, emergency department visits, outpatient visits, and coronary revascularizations.  (Costs will also include non-CAD-related but test related costs.)</description>
  </other_outcome>
  <other_outcome>
    <measure>Secondary Safety Endpoint</measure>
    <time_frame>4 years</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The secondary safety endpoint will be rates of serious test-related complications*.
*Serious test-related complications will include contrast-induced nephropathy, hematoma requiring transfusion, arteriovenous fistula, aneurysm formation, retroperitoneal bleed, arterial dissection and any surgery for test-related complications and cumulative CAD test-related effective biological radiation dose.</description>
  </other_outcome>
  <other_outcome>
    <measure>Quality of Life</measure>
    <time_frame>4 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>The tertiary endpoint will be general and angina-specific quality of life, as measured by the EQ-5D Health Survey and Seattle Angina Questionnaire, respectively.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1500</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Cardiac CT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients who undergo Cardiac CT (instead of Invasive Coronary Angiography)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Invasive Coronary Angiography</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients did not undergo Cardiac CT, went straight to Invasive Coronary Angiography</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cardiac CT</intervention_name>
    <description>Perform a non-invasive Cardiac CT Angiogram</description>
    <arm_group_label>Cardiac CT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Invasive Coronary Angiography</intervention_name>
    <description>Patient undergoes Invasive Coronary Angiography</description>
    <arm_group_label>Invasive Coronary Angiography</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA

          1. Age &gt;18 years

          2. Patients providing written informed consent

          3. Scheduled to undergo clinically-indicated non-emergent invasive coronary angiography
             with an ACC/AHA Class II indication

        EXCLUSION CRITERIA

          1. Known CAD (myocardial infarction, PCI, CABG)

          2. ACC/AHA Class I or III indication for ICA

          3. Non-cardiac illness with life expectancy &lt;2 years

          4. Inability to provide written informed consent

          5. Concomitant participation in another clinical trial in which subject is subject to
             investigational drug or device

          6. Pregnant women

          7. Allergy to iodinated contrast agent

          8. Serum creatinine ≥1.5 mg/dl or Glomerular Filtration Rate &lt;30 ml/min

          9. Uncontrolled Baseline irregular heart rhythm (e.g., atrial fibrillation, etc.)

         10. Heart rate ≥100 beats per minute

        12) Systolic blood pressure ≤90 mm Hg 13) Contraindications to β blockers or nitroglycerin
        14) Known complex congenital heart disease 15) Body mass index &gt;35
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James Min, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cedars Sinai</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dan Gebow, PhD</last_name>
    <role>Study Director</role>
    <affiliation>MDDX LLC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hyuk-Jae Chang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Severance Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dan Gebow, PhD</last_name>
    <email>dgebow@mddx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Walter Reed Medical Center</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Todd Villines, MD</last_name>
    </contact>
    <investigator>
      <last_name>Todd Villines, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>FACTS</name>
      <address>
        <city>Hyderabad</city>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ravi Bathina, MD</last_name>
      <email>ravibathina@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Ravi Bathina, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro Cardiologico Monzino</name>
      <address>
        <city>Monzino</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gianluca Pontone, MD</last_name>
    </contact>
    <investigator>
      <last_name>Daniele Andreini</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kangwon National University Hospital</name>
      <address>
        <city>Seoul</city>
        <state>South Korea</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>HER AE-YOUNG, MD</last_name>
      <phone>82-10-6375-3863</phone>
    </contact>
    <investigator>
      <last_name>HER AE-YOUNG, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gangneung Asan Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shin Dae-Hee, MD</last_name>
      <phone>82-10-9986-1291</phone>
    </contact>
    <investigator>
      <last_name>Shin Dae-Hee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>HYUK-JAE CHANG, MD</last_name>
      <phone>82-2-2228-8460</phone>
    </contact>
    <investigator>
      <last_name>HYUK-JAE CHANG, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ajou University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Choi So-Yeon, MD</last_name>
      <phone>82-10-8632-5690</phone>
    </contact>
    <investigator>
      <last_name>Choi So-Yeon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Korea university, Guro hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>KIM JIN-WON, MD</last_name>
      <phone>82-10-6380-3006</phone>
    </contact>
    <investigator>
      <last_name>Kim JIN-WON, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yeongnam University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>KIM WOONG, MD</last_name>
      <phone>82-10-4504-1507</phone>
    </contact>
    <investigator>
      <last_name>KIM WOONG, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gangnam Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>CHOI EUI-YOUNG, MD</last_name>
      <phone>82-10-2521-8022</phone>
    </contact>
    <investigator>
      <last_name>CHOI EUI-YOUNG, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pusan National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Choi Junghyun, MD</last_name>
      <phone>82-10-7133-3594</phone>
    </contact>
    <investigator>
      <last_name>Choi Junghyun, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
    <country>India</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <lastchanged_date>September 21, 2013</lastchanged_date>
  <firstreceived_date>February 22, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Coronary Artery Disease</keyword>
  <keyword>Cardiac CT</keyword>
  <keyword>Catheterization</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
